Targeted alpha therapy: One compound holds promise for unified cancer care

ORNL is a leader both in developing advanced radiotherapies and in providing the radioisotopes needed for those therapies. According to Karen Sikes, director of the National Isotope Development Center, the lab is home to more than 300 isotopes that are available to researchers and others. Besides actinium-225, medical radioisotopes on the list include lead-212, an in vivo alpha emitter generator going through clinical trials for the treatment of liver, prostate, skin and other cancers, and actinium-227, which decays to the alpha emitter radium-223, found in the approved drug Xofigo used to treat prostate cancers that have spread to bone.